Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Xiqiao Zhou
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06762223CT.gov Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | — | Not Yet Recruiting | — | — | — |
NCT06449833CT.gov Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | — | Recruiting | — | — | — |
NCT06085703CT.gov Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial | — | Completed | — | — | — |
NCT06218342CT.gov Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease | — | Unknown | — | — | — |
NCT06059287CT.gov The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Henagliflozin (this asset) | Xiqiao Zhou | Approved | B · 59 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Orlistat | Affiliated Hospital of Nantong University | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Henagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BB · 65 |
| Obesity Disorder | — | P4 | BB · 65 |
| Prediabetes Syndrome | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Henagliflozin in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/henagliflozin-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →